158 related articles for article (PubMed ID: 37072477)
1. A novel risk model for predicting early relapse in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem-cell transplantation.
Yuan XL; Lai XY; Wu YB; Yang LX; Shi JM; Liu LZ; Yu J; Zhao YM; Zheng WY; He JS; Sun J; Wu WJ; Zhao Y; Ye YS; Cai Z; Huang H; Luo Y
Bone Marrow Transplant; 2023 Jul; 58(7):801-810. PubMed ID: 37072477
[TBL] [Abstract][Full Text] [Related]
2. Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Qin YZ; Chen Y; Xu LP; Wang Y; Zhang XH; Chen H; Zhao XS; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2018 Jan; 24(1):163-168. PubMed ID: 28939454
[TBL] [Abstract][Full Text] [Related]
3. WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates.
Cho BS; Min GJ; Park SS; Shin SH; Yahng SA; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
Biol Blood Marrow Transplant; 2019 Oct; 25(10):1925-1932. PubMed ID: 31173897
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
[TBL] [Abstract][Full Text] [Related]
6. [Clinical Outcomes and Prognostic Factors of Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia].
Lou D; Liu L; Yan XQ; Gu FN; Zhang YP; Qin WW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1577-1585. PubMed ID: 36208269
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.
Kong J; Gao MG; Qin YZ; Wang Y; Yan CH; Sun YQ; Chang YJ; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XS
BMC Cancer; 2022 Jan; 22(1):11. PubMed ID: 34979982
[TBL] [Abstract][Full Text] [Related]
8. Acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation: a retrospective study from a single institution.
Lin CH; Chen TC; Shih YH; Chou CW; Hsu CY; Li PH; Teng CJ
J Int Med Res; 2022 Feb; 50(2):3000605221078466. PubMed ID: 35187981
[TBL] [Abstract][Full Text] [Related]
9. FLT3-ITD Allelic Ratio and NPM1 Mutation Do Not Impact Outcomes in Acute Myeloid Leukemia Patients with FLT3-ITD after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Propensity Score- Matching Study.
Zhou C; Zheng F; Xu L; Zhang X; Chang Y; Mo X; Sun Y; Huang X; Wang Y
Transplant Cell Ther; 2023 Jul; 29(7):456.e1-456.e11. PubMed ID: 37028555
[TBL] [Abstract][Full Text] [Related]
10. Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Tong X; Li M; Jin J; Li Y; Li L; Peng Y; Huang L; Xu B; Meng F; Mao X; Huang L; Huang W; Zhang D
Int J Cancer; 2023 May; 152(10):2123-2133. PubMed ID: 36594582
[TBL] [Abstract][Full Text] [Related]
11. Interferon-α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study.
Mo XD; Wang Y; Zhang XH; Xu LP; Yan CH; Chen H; Chen YH; Qin YZ; Liu KY; Huang XJ
Oncologist; 2018 Nov; 23(11):1349-1357. PubMed ID: 30076280
[TBL] [Abstract][Full Text] [Related]
12. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for post-transplant relapse and survival in younger adult patients with t(8;21)(q22;q22) acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: A multicenter retrospective study.
Zhou W; Chen G; Gong D; Gao Y; Yu L
Front Oncol; 2023; 13():1138853. PubMed ID: 36845681
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and Relapse Prediction Model of Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Acute Leukemia].
Wang XN; Zhang Y; Liu XW; Ren J; Zhao J; He PC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):696-702. PubMed ID: 34105459
[TBL] [Abstract][Full Text] [Related]
15. Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience.
Hoff FW; Chung SS; Patel PA; Premnath N; Khatib J; Tadic-Ovcina M; AhmedRabie A; Helton D; Yohannes S; Shahan J; Patel H; Geethakumari PR; Vusirikala M; Collins RH; Madanat YF
Transpl Immunol; 2023 Apr; 77():101808. PubMed ID: 36842566
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of adult patients with acute myeloid leukemia and unsuccessful cytogenetic analysis undergoing allogeneic hematopoietic stem cell transplantation.
Vasudevan Nampoothiri R; Chen S; Pasic I; Al-Shaibani Z; Lam W; Michelis FV; Kim DDH; Viswabandya A; Gerbitz A; Lipton JH; Kumar R; Mattsson J; Law AD
Hematol Oncol Stem Cell Ther; 2021 Jun; 14(2):134-140. PubMed ID: 33049225
[TBL] [Abstract][Full Text] [Related]
17. Pretransplantation minimal residual disease monitoring by multiparameter flow cytometry predicts outcomes of AML patients receiving allogeneic hematopoietic stem cell transplantation.
Zhang Y; Wang P; Cassady K; Zou Z; Li Y; Deng X; Yang W; Peng X; Zhang X; Feng Y
Transpl Immunol; 2022 Jun; 72():101596. PubMed ID: 35390479
[TBL] [Abstract][Full Text] [Related]
18. [Effect of minimal residual disease monitoring by multiparameter flow cytometry pre-conditioning on prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Lu Y; Wu T; Wang H; Zhao YL; Cao XY; Liu DY; Zhang JP; Xiong M; Zhou JR; Sun RJ; Wei ZJ; Ji SQ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):118-123. PubMed ID: 28279035
[No Abstract] [Full Text] [Related]
19. [Analysis of risk factors of relapse after allogeneic hematopoietic stem cell transplantation in patients with t (8;21) acute myeloid leukemia].
Guo WW; Liu X; Pang AM; Zhai WH; Yang DL; Chen X; Ma QL; He Y; Zhang RL; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):998-1004. PubMed ID: 35045670
[No Abstract] [Full Text] [Related]
20. Efficacy of myeloablative allogeneic hematopoietic stem cell transplantation in adult patients with MLL-ELL-positive acute myeloid leukemia.
Muto T; Takeuchi M; Yamazaki A; Sugita Y; Tsukamoto S; Sakai S; Takeda Y; Mimura N; Ohwada C; Sakaida E; Aotsuka N; Iseki T; Nakaseko C
Int J Hematol; 2015 Jul; 102(1):86-92. PubMed ID: 25758097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
